Familial endocrine neoplasia syndromes multiple endocrine neoplasia (MEN) type 1, MEN type 2 and von Hippel Lindau (VHL) can now be diagnosed genetically in childhood. Paediatric endocrinologists must therefore be prepared to investigate and manage these children. This paper provides an overview of the major features of these syndromes and suggests protocols for regular screening of children known to be at risk of developing these disorders.

Johnston LJ, Chew SL, Trainer PJ, Reznek R, Grossman AB, Besser GM, Monson JP, Savage MO: Screening children at risk of developing inherited endocrine neoplasia syndromes. Clin Endocrinol 2000;52:127–136.
Trump D, Farren B, Wooding C, Pang JT, Besser GM, Buchanan KD, Edwards CR, Heath DA, Jackson CE, Jansen S, Lips K, Monson JP, O’Halloran D, Sampson J, Shalet SM, Wheeler MH, Zink A, Thakker RV: Clinical studies of multiple endocrine neoplasia type 1 (MEN1). Quart J Med 1996;89:653–669.
Bassett JH, Forbes SA, Pannett AA, Lloyd SE, Christie PT, Wooding C, Harding B, Besser GM, Edwards CR, Monson JP, Sampson J, Wass JA, Wheeler MH, Thakker RV: Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet 1998;62:232–244.
Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL, Marx SJ: Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276:404–407.
Hoff AO, Gagel RF: Multiple endocrine neoplasia types 1 and 2: Phenotype, genotype, diagnosis and therapeutic plan with special reference to children and adolescents. Curr Opin Endocrinol Diabetes 1997;4:91–99.
Teh BT: Recent advances in multiple endocrine neoplasia type 1. Curr Opin Endocrinol Diabetes 1998;5:35–39.
Skogseid B, Rastad J, Oberg K: Multiple endocrine neoplasia type I: Clinical features and screening. Endocrinol Metab Clin North Am 1994;23:1–18.
Gagel RF, Cote GJ, Martins Bugalho MJ, Boyd AE, III, Cummings T, Goepfert H, Evans DB, Cangir A, Khorana S, Schultz PN: Clinical use of molecular information in the management of multiple endocrine neoplasia type 2A. J Intern Med 1995;238:333–341.
Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JB, Gardner E, Ponder MA, Frilling A, Jackson CE, Lehnert H, et al: Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genet 1994;6:70–74.
Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SAJ, Goodfellow PJ, Donis-Keller H: Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Nat Acad Sci USA 1994;91:1579–1583.
Zedenius J, Larsson C, Bergholm U, Bovee J, Svensson A, Hallengren B, Grimelius L, Backdahl M, Weber G, Wallin G: Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1995;80:3088–3090.
Gagel RF, Robinson MF, Donovan DT, Alford BR: Clinical review 44: Medullary thyroid carcinoma: Recent progress. J Clin Endocrinol Metab 1993;76:809–814.
Skinner MA, Debenedetti MK, Moley JF, Norton JA, Wells SA Jr: Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. J Pediatr Surg 1996;31:177–181.
Gagel RF, Tashjian AH Jr, Cummings T, Papathanasopoulos N, Kaplan MM, Delellis RA, Wolfe HJ, Reichlin S: The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med 1988;318:478–484.
Howe JR, Norton JA, Wells SA Jr: Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: Results of long-term follow-up. Surgery 1993;114:1070–1077.
Kraimps JL, Denizot A, Carnaille B, Henry JF, Proye C, Bacourt F, Sarfati E, Dupond JL, Maes B, Travagli JP, Boneu A, Roger P, Houdent C, Barbier J, Modigliani E: Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: Retrospective French multicentric study. Groupe d’Etude des Tumeurs a Calcitonine (GETC, French Calcitonin Tumors Study Group), French Association of Endocrine Surgeons. World J Surg 1996;20:808–812.
Maher ER, Yates JR, Harries R, Benjamin C, Harris R, Moore AT, Ferguson-Smith MA: Clinical features and natural history of von Hippel-Lindau disease. Quart J Med 1990;77:1151–1163.
Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Nat Acad Sci USA 1996;93:10595–10599.
Iliopoulos O, Ohh M, Kaelin WG Jr: pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Nat Acad Sci USA 1998;95:11661–11666.
Maher ER, Webster AR, Richards FM, Green JS, Crossey PA, Payne SJ, Moore AT: Phenotypic expression in von Hippel-Lindau disease: Correlations with germline VHL gene mutations. J Med Genet 1996;33:328–332.
Neumann HP, Eggert HR, Scheremet R, Schumacher M, Mohadjer M, Wakhloo AK, Volk B, Hettmannsperger U, Riegler P, Schollmeyer P: Central nervous system lesions in von Hippel-Lindau syndrome. J Neurol Neurosurg Psychiatry 1992;55:898–901.
Choyke PL, Glenn GM, Walther MM, Zbar B, Weiss GH, Alexander RB, Hayes WS, Long JP, Thakore KN, Linehan WM: The natural history of renal lesions in von Hippel-Lindau disease: A serial CT study in 28 patients. Am J Roentgenol 1992;159:1229–1234.
Newbould EC, Ross GA, Dacie JE, Bouloux PM, Besser GM, Grossman A: The use of venous catheterisation in the diagnosis and localisation of bilateral phaeochromocytomas. Clin Endocrinol 1991;35:55–59.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.